Abstract
Objectives: To compare the risk of cancer between BRCA1 or BRCA2 mutation-positive and -negative families.
Methods: We assessed standardized incidence ratios (SIR) in 107 Finnish breast cancer families (12 BRCA1, 11 BRCA2, 84 non-BRCA1/2) with confirmed genealogy. The observed numbers of cancer cases were compared to the expected ones; both numbers were based on the population-based Finnish Cancer Registry.
Results: Risk of ovarian cancer for first-degree relatives was high in BRCA1 (SIR 29, 95% confidence interval 9.4–68) and in BRCA2 families (SIR 18, 8.3–35), but not increased for non-BRCA1/2 families (SIR 1.0, 0.2–2.9). The SIR for subsequent ovarian cancer among breast cancer patients was 61 (20–142), 38 (11–98), and 0 (0–4.2), respectively. The risk of subsequent new breast cancer among breast cancer patients was equally high in BRCA1 families (SIR 11, 3.6–26) and in BRCA2 families (SIR 10, 3.3–24) and somewhat lower in mutation-negative families (SIR 3.7, 2.1–6.1). The risk of breast cancer among relatives was markedly increased in all three groups. The only elevated SIR, besides breast and ovarian, was that for prostate cancer in BRCA2 families (SIR 4.9, 1.8–11).
Conclusions: The excess risk of breast cancer in non-BRCA1/2 families suggests the existence of another predisposition gene which seems not to be linked with increased risk of ovarian cancer.
Similar content being viewed by others
References
Colditz GA, Willett WC, Hunter DJ, et al. (1993) Family history, age, and risk of breast cancer. Prospective data from the Nurses' Health Study. JAMA 270: 338–343.
Tulinius H, Sigvaldason H, Olafsdottir GH, et al. (1992) Epidemiology of breast cancer in families in Iceland. J Med Genet 29: 158–164.
Houlston RS, McCarter E, Parbhoo S, et al. (1992) Family history and risk of breast cancer. J Med Genet 29: 154–157.
Schildkraut J, Risch N, Thompson W (1989) Evaluating genetic association among ovarian, breast and endometrial cancer, evidence for a breast/ovarian cancer relationship. Am J Hum Genet 45: 521–529.
Miki Y, Swensen J, Shattuck-Eidens D, et al. (1994) A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266: 66–71.
Wooster R, Bignell G, Lancaster J, et al. (1995) Identification of the breast cancer susceptibility gene BRCA2. Nature 378: 789–792.
Ford D, Easton DF, Bishop DT, et al. (1994) Risks of cancer in BRCA1-mutation carriers. Lancet 343: 692–695.
Easton D, Ford D, Bishop T, et al. (1995) Breast and ovarian cancer incidence in BRCA1-mutation carriers. Am J Hum Genet 56: 265–271.
Ford D, Easton DF, Stratton M, et al. (1998) Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am J Hum Genet 62: 676–689.
Easton D, Consortium BCL (1999) Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst 91: 1310–1316.
Struewing JP, Hartge PW, Wacholder S, et al. (1997) The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 336: 1401–1408.
Warner E, Foulkes W, Goodwin P, et al. (1999) Prevalence and penetrance of BRCA1 and BRCA2 gene mutations in unselected Ashkenazi Jewish women with breast cancer. J Natl Cancer Inst 91: 1241–1247.
Thorlacius S, Struewing JP, Hartge P, et al. (1998) Population-based study of risk of breast cancer in carriers of BRCA2 mutation. Lancet 352: 1337–1339.
Peto J, Collins N, Barfoot R, et al. (1999) Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. J Natl Cancer Inst 91: 943–949.
Hopper J, Southey MC, Dite GS, et al. (1999) Population-based estimate of the average age-specific cumulative risk of breast cancer for a defined set of protein-truncating mutations in BRCA1 and BRCA2. Cancer Epidemiol 8: 741–747.
Johansson O, Loman N, Möller T, Kristoffersson U, Borg Å, Olsson H (1999) Incidence of malignant tumours in relatives of BRCA1 and BRCA2 germline mutation carriers. Eur J Cancer 35: 1248–1257.
Vehmanen P, Friedman LS, Eerola H, et al. (1997) Low proportion of BRCA1 and BRCA2 mutations in Finnish breast cancer families, evidence for additional susceptibility genes. Hum Mol Genet 6: 2309–2315.
Eerola H, Blomqvist C, Pukkala E, Pyrhönen S, Nevanlinna H (2000) Familial breast cancer in Southern Finland: How prevalent are breast cancer families and can we trust the family history reported by the patients? Eur J Cancer 36: 1143–1148.
Vehmanen P, Friedman LS, Eerola H, et al. (1997) A low proportion of BRCA2 mutations in Finnish breast cancer families. Am J Hum genet 60: 1050–1058.
Vahteristo P, Eerola H, Tamminen A, Blomqvist C, Nevanlinna H (2001) A probability model for predicting BRCA1 and BRCA2 mutations in breast and breast-ovarian cancer families. Br J Cancer 84: 704–708.
Sarantaus L, Huusko P, Eerola H, et al. (2000) Multiple founder effects and geographical clustering of BRCA1 and BRCA2 families in Finland. Eur J Hum Genet 8: 757–763.
Huusko P, Pääkkönen K, Launonen V, et al. (1998) Evidence for founder mutations in Finnish BRCA1 and BRCA2 families. Am J Hum Genet 62: 1544–1548.
Syrjäkoski K, Vahteristo P, Eerola H, et al. (2000) Population-based study of BRCA1 and BRCA2 mutations in 1035 unselected Finnish breast cancer patients. J Natl Cancer Inst 92: 1529–1531.
Teppo L, Pukkala E, Lehtonen M (1994) Data quality and quality control of a population-based cancer registry. Acta Oncol 33: 365–369.
SPSS for Windows, Rel 8.0.1.1998. Chicago: SPSS.
Statview for PowerPC, Rel 4.5.1, 1995. Berkeley, CA: Abacus Concepts.
Claus EB, Schildkraut JM, Thompson WD, et al. (1996) The genetic attributable risk of breast and ovarian cancer. Cancer 77: 2318–2324.
Gayther SA, Mangion J, Russel P, et al. (1997) Variation of risks of breast and ovarian cancer associated with different germline mutations of the BRCA2 gene. Nat Genet 15: 103–105.
Teppo L, Pukkala E, Saxen E (1985) Multiple cancer — an epidemiologic exercise in Finland. J Natl Cancer Inst 75: 207–217.
Kainu T, Juo SH, Desper R, et al. (2000) Somatic deletions in hereditary breast cancers implicate 13q21 as a putative novel breast cancer susceptibility locus. Proc Natl Acad Sci 97: 9693–9708.
Easton DF, Steele L, Fields P, et al. (1997) Cancer risks in two large breast cancer families linked to BRCA2 on chromosome 13q12-13. Am J Hum Genet 61: 120–128.
Love RR, Evans AM, Josten DM (1985) The accuracy of patient reports of a family history of cancer. J Chron Dis 38: 289–293.
Kerber RA, Slattery ML (1997) Comparison of self-reported and database-linked family history of cancer data in a case-control study. Am J Epidemiol 146: 244–248.
Gladstone A, Adatto P, Cunningham J, et al. (1998) Family history of cancer in patients with glioma, a validation study of accuracy. J Natl Cancer Inst 90: 543–544.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Eerola, H., Pukkala, E., Pyrhönen, S. et al. Risk of cancer in BRCA1 and BRCA2 mutation-positive and -negative breast cancer families (Finland). Cancer Causes Control 12, 739–746 (2001). https://doi.org/10.1023/A:1011272919982
Issue Date:
DOI: https://doi.org/10.1023/A:1011272919982